Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02390050 · ClinicalTrials.gov registry record · Phase 2
A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Theracos.
- Completed
- Registry status
- Phase 2
- Development phase
- 292
- Enrollment target
NCT02390050 is a Phase 2 study that has completed, run by Theracos. The registered enrollment target is 292 participants.
The verdict
NCT02390050, a Phase 2 study, has completed, sponsored by Theracos.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 292 participants
- Enrollment target
Study Summary
The purpose of this study was to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM). Bexagliflozin is an orally administered drug for the treatment of T2DM and is classified as a Sodium Glucose co-Transporter 2 (SGLT2) Inhibitor. This study was to enroll both treatment naive and those subjects previously treated with one oral hypoglycemic agent (OHA). Approximately 320 subjects eligible for randomization was to receive bexagliflozin tablets, 5, 10, 20 mg or placebo, once daily for 12 weeks in an outpatient setting.
Interventions
- DRUG Bexagliflozin tablets
- DRUG Bexagliflozin tablets, placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 292 participants |
| Start Date | 2015-05-12 |
| Est. Completion | 2016-06-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02390050
The ClinicalTrials.gov registry entry for NCT02390050 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 292 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theracos, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bexagliflozin tablets is the first listed.
NCT02390050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02390050 about?
NCT02390050 is a clinical study titled "A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus". The purpose of this study was to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM). Bexagliflozin is an orally administered drug for the treatment of T2DM and is classified as a Sodium Glucose co-Transporter 2 (SGLT2) I...
What is the current status of trial NCT02390050?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 292 participants. The study started on 2015-05-12. Estimated completion is 2016-06-03.
What interventions are being tested in trial NCT02390050?
The interventions under investigation include: Bexagliflozin tablets (DRUG), Bexagliflozin tablets, placebo (DRUG).
Who is sponsoring clinical trial NCT02390050?
This trial is sponsored by Theracos, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.